- Home
- SKYW vs DVAX Comparison
SKYW vs DVAX Comparison
Compare SKYW & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYW
- DVAX
- Stock Information
- Founded
- SKYW 1972
- DVAX 1996
- Country
- SKYW United States
- DVAX United States
- Employees
- SKYW N/A
- DVAX N/A
- Industry
- SKYW Air Freight/Delivery Services
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- SKYW Consumer Discretionary
- DVAX Health Care
- Exchange
- SKYW Nasdaq
- DVAX Nasdaq
- Market Cap
- SKYW 4.6B
- DVAX 1.3B
- IPO Year
- SKYW N/A
- DVAX 2004
- Fundamental
- Price
- SKYW $104.70
- DVAX $9.78
- Analyst Decision
- SKYW Strong Buy
- DVAX Buy
- Analyst Count
- SKYW 4
- DVAX 4
- Target Price
- SKYW $126.75
- DVAX $26.50
- AVG Volume (30 Days)
- SKYW 388.7K
- DVAX 2.0M
- Earning Date
- SKYW 10-30-2025
- DVAX 11-06-2025
- Dividend Yield
- SKYW N/A
- DVAX N/A
- EPS Growth
- SKYW 132.99
- DVAX N/A
- EPS
- SKYW 9.81
- DVAX N/A
- Revenue
- SKYW $3,840,870,000.00
- DVAX $316,268,000.00
- Revenue This Year
- SKYW $15.56
- DVAX $23.23
- Revenue Next Year
- SKYW $4.91
- DVAX $16.57
- P/E Ratio
- SKYW $10.62
- DVAX N/A
- Revenue Growth
- SKYW 20.45
- DVAX 26.66
- 52 Week Low
- SKYW $74.70
- DVAX $9.20
- 52 Week High
- SKYW $135.57
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- SKYW 34.71
- DVAX 44.09
- Support Level
- SKYW $103.03
- DVAX $9.20
- Resistance Level
- SKYW $106.51
- DVAX $9.94
- Average True Range (ATR)
- SKYW 3.55
- DVAX 0.31
- MACD
- SKYW -1.67
- DVAX -0.01
- Stochastic Oscillator
- SKYW 7.78
- DVAX 51.82
About SKYW SkyWest Inc.
SkyWest Inc offers commercial air services in the United States, Canada, Mexico, and the Caribbean. Additionally, it leases aircraft to capable users to help generate revenue. Generally, SkyWest provides regional flights, and utilizes its smaller, lower-cost aircraft to carry passengers that booked tickets through airlines. It partners with carriers across the world to fly and operate aircraft for a fee. SkyWest may use the carriers's brand and ground support to coordinate marketing and easily transport passengers. The company has two reportable segments: SkyWest Airlines, which generates maximum revenue, and SkyWest Leasing.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.